

WE CLAIM:

1. A method of treating or preventing obesity in a human subject comprising administering to said subject an effective amount of an amylin or an amylin agonist.

2. A method according to claim 1 wherein said amylin agonist is an amylin agonist analogue.

3. A method according to claim 2 wherein said amylin agonist analogue is ^{25,28,29}Pro-h-amylin.

4. A method according to claim 1 wherein said amylin or amylin agonist is administered subcutaneously.

5. A method according to claim 4 wherein said amylin or amylin agonist is administered from 1 to 4 times per day.

6. A method according to claim 5 wherein said amylin or amylin agonist is administered in an amount from 30 μ g per dose to 300 μ g/dose.

7. A method according to claim 6 wherein said amylin or amylin agonist is administered three times per day in an amount of about 60 μ g per dose.

8. A method according to claim 6 wherein said amylin or amylin agonist is administered four times per day in an amount of about 60 μ g per dose.

9. A method according to claim 7 or claim 8 wherein an amylin agonist is administered.

10. A method according to claim 9 wherein said amylin agonist is ^{25,28,29}Pro-h-amylin.

11. A method of reducing insulin-induced weight gain in a human subject taking insulin comprising administering to said subject an effective amount of an amylin or an amylin agonist.

12. A method according to claim 11 wherein an amylin agonist is administered.

13. A method according to claim 11 wherein said amylin agonist is ^{25,28,29}Pro-h-amylin.

14. A method according to claim 11 wherein said subject has diabetes mellitus.

15. A method according to claim 14 wherein said subject has type 1 diabetes mellitus.

Add
B1